0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global PDE Inhibitors for COPD Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-25J19620
Home | Market Reports | Health| Health Conditions| Respiratory Conditions
Global PDE Inhibitors for COPD Market Research Report 2025
BUY CHAPTERS

Global PDE Inhibitors for COPD Market Research Report 2025

Code: QYRE-Auto-25J19620
Report
September 2025
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

PDE Inhibitors for COPD Market Size

The global market for PDE Inhibitors for COPD was valued at US$ 443 million in the year 2024 and is projected to reach a revised size of US$ 641 million by 2031, growing at a CAGR of 5.3% during the forecast period.

PDE Inhibitors for COPD Market

PDE Inhibitors for COPD Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on PDE Inhibitors for COPD competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
PDE inhibitors for COPD are a class of drugs specifically targeting chronic obstructive pulmonary disease by selectively inhibiting the PDE4 isoenzyme, thereby enhancing intracellular cAMP signaling to achieve anti-inflammatory effects and improved airway function. Representative compounds include Roflumilast, administered as oral tablets for long-term management of patients with moderate to severe chronic bronchitis and airflow limitation. Upstream raw materials include high-purity small-molecule intermediates such as piperazine derivatives, pyridine compounds, and amide derivatives. Major suppliers are concentrated in China, India, and Europe/USA, with leading companies such as Sun Pharmaceutical, Hetero Labs, Huahai Pharmaceutical, and Lonza providing stable raw material supply and robust synthesis capabilities.
Downstream customers primarily consist of global pharmaceutical firms, generic drug manufacturers, and healthcare institutions. Finished formulations are distributed to hospitals, specialty clinics, and retail pharmacies. Key international clients include Pfizer, Eli Lilly, and AstraZeneca. Driven by the growing number of COPD patients and the increasing focus on precision medicine, demand for PDE inhibitors emphasizes safety, efficacy, and stability. This trend also encourages upstream raw material and intermediate suppliers to optimize production processes and expand capacity, supporting sustainable growth across the entire industry chain.
In 2024, the global average price of PDE inhibitors for COPD is approximately USD 6.4 per unit (where "unit" refers to the smallest packaged dosage form, such as a tablet, capsule, or vial), with total sales reaching about 69.22 million units.
North American market for PDE Inhibitors for COPD is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for PDE Inhibitors for COPD is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of PDE Inhibitors for COPD include AstraZeneca, Verona Pharma, Arcutis Biotherapeutics, Torrent Pharmaceuticals, MSN Laboratories, STADA Arzneimittel, Viatris, Zydus Cadila Healthcare, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PDE Inhibitors for COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PDE Inhibitors for COPD.
The PDE Inhibitors for COPD market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PDE Inhibitors for COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PDE Inhibitors for COPD manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of PDE Inhibitors for COPD Market Report

Report Metric Details
Report Name PDE Inhibitors for COPD Market
Accounted market size in year US$ 443 million
Forecasted market size in 2031 US$ 641 million
CAGR 5.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • PDE4
  • PDE3/4
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, Verona Pharma, Arcutis Biotherapeutics, Torrent Pharmaceuticals, MSN Laboratories, STADA Arzneimittel, Viatris, Zydus Cadila Healthcare
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of PDE Inhibitors for COPD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of PDE Inhibitors for COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is PDE Inhibitors for COPD Market growing?

Ans: The PDE Inhibitors for COPD Market witnessing a CAGR of 5.3% during the forecast period 2025-2031.

What is the PDE Inhibitors for COPD Market size in 2031?

Ans: The PDE Inhibitors for COPD Market size in 2031 will be US$ 641 million.

Who are the main players in the PDE Inhibitors for COPD Market report?

Ans: The main players in the PDE Inhibitors for COPD Market are AstraZeneca, Verona Pharma, Arcutis Biotherapeutics, Torrent Pharmaceuticals, MSN Laboratories, STADA Arzneimittel, Viatris, Zydus Cadila Healthcare

What are the Application segmentation covered in the PDE Inhibitors for COPD Market report?

Ans: The Applications covered in the PDE Inhibitors for COPD Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the PDE Inhibitors for COPD Market report?

Ans: The Types covered in the PDE Inhibitors for COPD Market report are PDE4, PDE3/4

1 PDE Inhibitors for COPD Market Overview
1.1 Product Definition
1.2 PDE Inhibitors for COPD by Type
1.2.1 Global PDE Inhibitors for COPD Market Value Comparison by Type (2024 VS 2031)
1.2.2 PDE4
1.2.3 PDE3/4
1.3 PDE Inhibitors for COPD by Application
1.3.1 Global PDE Inhibitors for COPD Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global PDE Inhibitors for COPD Market Size Estimates and Forecasts
1.4.1 Global PDE Inhibitors for COPD Revenue 2020-2031
1.4.2 Global PDE Inhibitors for COPD Sales 2020-2031
1.4.3 Global PDE Inhibitors for COPD Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 PDE Inhibitors for COPD Market Competition by Manufacturers
2.1 Global PDE Inhibitors for COPD Sales Market Share by Manufacturers (2020-2025)
2.2 Global PDE Inhibitors for COPD Revenue Market Share by Manufacturers (2020-2025)
2.3 Global PDE Inhibitors for COPD Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of PDE Inhibitors for COPD, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PDE Inhibitors for COPD, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PDE Inhibitors for COPD, Product Type & Application
2.7 Global Key Manufacturers of PDE Inhibitors for COPD, Date of Enter into This Industry
2.8 Global PDE Inhibitors for COPD Market Competitive Situation and Trends
2.8.1 Global PDE Inhibitors for COPD Market Concentration Rate
2.8.2 The Global 5 and 10 Largest PDE Inhibitors for COPD Players Market Share by Revenue
2.8.3 Global PDE Inhibitors for COPD Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global PDE Inhibitors for COPD Market Scenario by Region
3.1 Global PDE Inhibitors for COPD Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global PDE Inhibitors for COPD Sales by Region: 2020-2031
3.2.1 Global PDE Inhibitors for COPD Sales by Region: 2020-2025
3.2.2 Global PDE Inhibitors for COPD Sales by Region: 2026-2031
3.3 Global PDE Inhibitors for COPD Revenue by Region: 2020-2031
3.3.1 Global PDE Inhibitors for COPD Revenue by Region: 2020-2025
3.3.2 Global PDE Inhibitors for COPD Revenue by Region: 2026-2031
3.4 North America PDE Inhibitors for COPD Market Facts & Figures by Country
3.4.1 North America PDE Inhibitors for COPD Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America PDE Inhibitors for COPD Sales by Country (2020-2031)
3.4.3 North America PDE Inhibitors for COPD Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe PDE Inhibitors for COPD Market Facts & Figures by Country
3.5.1 Europe PDE Inhibitors for COPD Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe PDE Inhibitors for COPD Sales by Country (2020-2031)
3.5.3 Europe PDE Inhibitors for COPD Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PDE Inhibitors for COPD Market Facts & Figures by Region
3.6.1 Asia Pacific PDE Inhibitors for COPD Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific PDE Inhibitors for COPD Sales by Region (2020-2031)
3.6.3 Asia Pacific PDE Inhibitors for COPD Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America PDE Inhibitors for COPD Market Facts & Figures by Country
3.7.1 Latin America PDE Inhibitors for COPD Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America PDE Inhibitors for COPD Sales by Country (2020-2031)
3.7.3 Latin America PDE Inhibitors for COPD Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa PDE Inhibitors for COPD Market Facts & Figures by Country
3.8.1 Middle East and Africa PDE Inhibitors for COPD Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa PDE Inhibitors for COPD Sales by Country (2020-2031)
3.8.3 Middle East and Africa PDE Inhibitors for COPD Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PDE Inhibitors for COPD Sales by Type (2020-2031)
4.1.1 Global PDE Inhibitors for COPD Sales by Type (2020-2025)
4.1.2 Global PDE Inhibitors for COPD Sales by Type (2026-2031)
4.1.3 Global PDE Inhibitors for COPD Sales Market Share by Type (2020-2031)
4.2 Global PDE Inhibitors for COPD Revenue by Type (2020-2031)
4.2.1 Global PDE Inhibitors for COPD Revenue by Type (2020-2025)
4.2.2 Global PDE Inhibitors for COPD Revenue by Type (2026-2031)
4.2.3 Global PDE Inhibitors for COPD Revenue Market Share by Type (2020-2031)
4.3 Global PDE Inhibitors for COPD Price by Type (2020-2031)
5 Segment by Application
5.1 Global PDE Inhibitors for COPD Sales by Application (2020-2031)
5.1.1 Global PDE Inhibitors for COPD Sales by Application (2020-2025)
5.1.2 Global PDE Inhibitors for COPD Sales by Application (2026-2031)
5.1.3 Global PDE Inhibitors for COPD Sales Market Share by Application (2020-2031)
5.2 Global PDE Inhibitors for COPD Revenue by Application (2020-2031)
5.2.1 Global PDE Inhibitors for COPD Revenue by Application (2020-2025)
5.2.2 Global PDE Inhibitors for COPD Revenue by Application (2026-2031)
5.2.3 Global PDE Inhibitors for COPD Revenue Market Share by Application (2020-2031)
5.3 Global PDE Inhibitors for COPD Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca PDE Inhibitors for COPD Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca PDE Inhibitors for COPD Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Verona Pharma
6.2.1 Verona Pharma Company Information
6.2.2 Verona Pharma Description and Business Overview
6.2.3 Verona Pharma PDE Inhibitors for COPD Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Verona Pharma PDE Inhibitors for COPD Product Portfolio
6.2.5 Verona Pharma Recent Developments/Updates
6.3 Arcutis Biotherapeutics
6.3.1 Arcutis Biotherapeutics Company Information
6.3.2 Arcutis Biotherapeutics Description and Business Overview
6.3.3 Arcutis Biotherapeutics PDE Inhibitors for COPD Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Arcutis Biotherapeutics PDE Inhibitors for COPD Product Portfolio
6.3.5 Arcutis Biotherapeutics Recent Developments/Updates
6.4 Torrent Pharmaceuticals
6.4.1 Torrent Pharmaceuticals Company Information
6.4.2 Torrent Pharmaceuticals Description and Business Overview
6.4.3 Torrent Pharmaceuticals PDE Inhibitors for COPD Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Torrent Pharmaceuticals PDE Inhibitors for COPD Product Portfolio
6.4.5 Torrent Pharmaceuticals Recent Developments/Updates
6.5 MSN Laboratories
6.5.1 MSN Laboratories Company Information
6.5.2 MSN Laboratories Description and Business Overview
6.5.3 MSN Laboratories PDE Inhibitors for COPD Sales, Revenue and Gross Margin (2020-2025)
6.5.4 MSN Laboratories PDE Inhibitors for COPD Product Portfolio
6.5.5 MSN Laboratories Recent Developments/Updates
6.6 STADA Arzneimittel
6.6.1 STADA Arzneimittel Company Information
6.6.2 STADA Arzneimittel Description and Business Overview
6.6.3 STADA Arzneimittel PDE Inhibitors for COPD Sales, Revenue and Gross Margin (2020-2025)
6.6.4 STADA Arzneimittel PDE Inhibitors for COPD Product Portfolio
6.6.5 STADA Arzneimittel Recent Developments/Updates
6.7 Viatris
6.7.1 Viatris Company Information
6.7.2 Viatris Description and Business Overview
6.7.3 Viatris PDE Inhibitors for COPD Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Viatris PDE Inhibitors for COPD Product Portfolio
6.7.5 Viatris Recent Developments/Updates
6.8 Zydus Cadila Healthcare
6.8.1 Zydus Cadila Healthcare Company Information
6.8.2 Zydus Cadila Healthcare Description and Business Overview
6.8.3 Zydus Cadila Healthcare PDE Inhibitors for COPD Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Zydus Cadila Healthcare PDE Inhibitors for COPD Product Portfolio
6.8.5 Zydus Cadila Healthcare Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PDE Inhibitors for COPD Industry Chain Analysis
7.2 PDE Inhibitors for COPD Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PDE Inhibitors for COPD Production Mode & Process Analysis
7.4 PDE Inhibitors for COPD Sales and Marketing
7.4.1 PDE Inhibitors for COPD Sales Channels
7.4.2 PDE Inhibitors for COPD Distributors
7.5 PDE Inhibitors for COPD Customer Analysis
8 PDE Inhibitors for COPD Market Dynamics
8.1 PDE Inhibitors for COPD Industry Trends
8.2 PDE Inhibitors for COPD Market Drivers
8.3 PDE Inhibitors for COPD Market Challenges
8.4 PDE Inhibitors for COPD Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global PDE Inhibitors for COPD Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global PDE Inhibitors for COPD Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global PDE Inhibitors for COPD Market Competitive Situation by Manufacturers in 2024
 Table 4. Global PDE Inhibitors for COPD Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global PDE Inhibitors for COPD Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global PDE Inhibitors for COPD Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global PDE Inhibitors for COPD Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market PDE Inhibitors for COPD Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of PDE Inhibitors for COPD, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of PDE Inhibitors for COPD, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of PDE Inhibitors for COPD, Product Type & Application
 Table 12. Global Key Manufacturers of PDE Inhibitors for COPD, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global PDE Inhibitors for COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PDE Inhibitors for COPD as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global PDE Inhibitors for COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global PDE Inhibitors for COPD Sales by Region (2020-2025) & (K Units)
 Table 18. Global PDE Inhibitors for COPD Sales Market Share by Region (2020-2025)
 Table 19. Global PDE Inhibitors for COPD Sales by Region (2026-2031) & (K Units)
 Table 20. Global PDE Inhibitors for COPD Sales Market Share by Region (2026-2031)
 Table 21. Global PDE Inhibitors for COPD Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global PDE Inhibitors for COPD Revenue Market Share by Region (2020-2025)
 Table 23. Global PDE Inhibitors for COPD Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global PDE Inhibitors for COPD Revenue Market Share by Region (2026-2031)
 Table 25. North America PDE Inhibitors for COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America PDE Inhibitors for COPD Sales by Country (2020-2025) & (K Units)
 Table 27. North America PDE Inhibitors for COPD Sales by Country (2026-2031) & (K Units)
 Table 28. North America PDE Inhibitors for COPD Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America PDE Inhibitors for COPD Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe PDE Inhibitors for COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe PDE Inhibitors for COPD Sales by Country (2020-2025) & (K Units)
 Table 32. Europe PDE Inhibitors for COPD Sales by Country (2026-2031) & (K Units)
 Table 33. Europe PDE Inhibitors for COPD Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe PDE Inhibitors for COPD Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific PDE Inhibitors for COPD Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific PDE Inhibitors for COPD Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific PDE Inhibitors for COPD Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific PDE Inhibitors for COPD Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific PDE Inhibitors for COPD Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America PDE Inhibitors for COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America PDE Inhibitors for COPD Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America PDE Inhibitors for COPD Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America PDE Inhibitors for COPD Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America PDE Inhibitors for COPD Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa PDE Inhibitors for COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa PDE Inhibitors for COPD Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa PDE Inhibitors for COPD Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa PDE Inhibitors for COPD Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa PDE Inhibitors for COPD Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global PDE Inhibitors for COPD Sales (K Units) by Type (2020-2025)
 Table 51. Global PDE Inhibitors for COPD Sales (K Units) by Type (2026-2031)
 Table 52. Global PDE Inhibitors for COPD Sales Market Share by Type (2020-2025)
 Table 53. Global PDE Inhibitors for COPD Sales Market Share by Type (2026-2031)
 Table 54. Global PDE Inhibitors for COPD Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global PDE Inhibitors for COPD Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global PDE Inhibitors for COPD Revenue Market Share by Type (2020-2025)
 Table 57. Global PDE Inhibitors for COPD Revenue Market Share by Type (2026-2031)
 Table 58. Global PDE Inhibitors for COPD Price (US$/Unit) by Type (2020-2025)
 Table 59. Global PDE Inhibitors for COPD Price (US$/Unit) by Type (2026-2031)
 Table 60. Global PDE Inhibitors for COPD Sales (K Units) by Application (2020-2025)
 Table 61. Global PDE Inhibitors for COPD Sales (K Units) by Application (2026-2031)
 Table 62. Global PDE Inhibitors for COPD Sales Market Share by Application (2020-2025)
 Table 63. Global PDE Inhibitors for COPD Sales Market Share by Application (2026-2031)
 Table 64. Global PDE Inhibitors for COPD Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global PDE Inhibitors for COPD Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global PDE Inhibitors for COPD Revenue Market Share by Application (2020-2025)
 Table 67. Global PDE Inhibitors for COPD Revenue Market Share by Application (2026-2031)
 Table 68. Global PDE Inhibitors for COPD Price (US$/Unit) by Application (2020-2025)
 Table 69. Global PDE Inhibitors for COPD Price (US$/Unit) by Application (2026-2031)
 Table 70. AstraZeneca Company Information
 Table 71. AstraZeneca Description and Business Overview
 Table 72. AstraZeneca PDE Inhibitors for COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. AstraZeneca PDE Inhibitors for COPD Product
 Table 74. AstraZeneca Recent Developments/Updates
 Table 75. Verona Pharma Company Information
 Table 76. Verona Pharma Description and Business Overview
 Table 77. Verona Pharma PDE Inhibitors for COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Verona Pharma PDE Inhibitors for COPD Product
 Table 79. Verona Pharma Recent Developments/Updates
 Table 80. Arcutis Biotherapeutics Company Information
 Table 81. Arcutis Biotherapeutics Description and Business Overview
 Table 82. Arcutis Biotherapeutics PDE Inhibitors for COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Arcutis Biotherapeutics PDE Inhibitors for COPD Product
 Table 84. Arcutis Biotherapeutics Recent Developments/Updates
 Table 85. Torrent Pharmaceuticals Company Information
 Table 86. Torrent Pharmaceuticals Description and Business Overview
 Table 87. Torrent Pharmaceuticals PDE Inhibitors for COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Torrent Pharmaceuticals PDE Inhibitors for COPD Product
 Table 89. Torrent Pharmaceuticals Recent Developments/Updates
 Table 90. MSN Laboratories Company Information
 Table 91. MSN Laboratories Description and Business Overview
 Table 92. MSN Laboratories PDE Inhibitors for COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. MSN Laboratories PDE Inhibitors for COPD Product
 Table 94. MSN Laboratories Recent Developments/Updates
 Table 95. STADA Arzneimittel Company Information
 Table 96. STADA Arzneimittel Description and Business Overview
 Table 97. STADA Arzneimittel PDE Inhibitors for COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. STADA Arzneimittel PDE Inhibitors for COPD Product
 Table 99. STADA Arzneimittel Recent Developments/Updates
 Table 100. Viatris Company Information
 Table 101. Viatris Description and Business Overview
 Table 102. Viatris PDE Inhibitors for COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Viatris PDE Inhibitors for COPD Product
 Table 104. Viatris Recent Developments/Updates
 Table 105. Zydus Cadila Healthcare Company Information
 Table 106. Zydus Cadila Healthcare Description and Business Overview
 Table 107. Zydus Cadila Healthcare PDE Inhibitors for COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Zydus Cadila Healthcare PDE Inhibitors for COPD Product
 Table 109. Zydus Cadila Healthcare Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. PDE Inhibitors for COPD Distributors List
 Table 113. PDE Inhibitors for COPD Customers List
 Table 114. PDE Inhibitors for COPD Market Trends
 Table 115. PDE Inhibitors for COPD Market Drivers
 Table 116. PDE Inhibitors for COPD Market Challenges
 Table 117. PDE Inhibitors for COPD Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of PDE Inhibitors for COPD
 Figure 2. Global PDE Inhibitors for COPD Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global PDE Inhibitors for COPD Market Share by Type: 2024 & 2031
 Figure 4. PDE4 Product Picture
 Figure 5. PDE3/4 Product Picture
 Figure 6. Global PDE Inhibitors for COPD Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global PDE Inhibitors for COPD Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Others
 Figure 11. Global PDE Inhibitors for COPD Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global PDE Inhibitors for COPD Market Size (2020-2031) & (US$ Million)
 Figure 13. Global PDE Inhibitors for COPD Sales (2020-2031) & (K Units)
 Figure 14. Global PDE Inhibitors for COPD Average Price (US$/Unit) & (2020-2031)
 Figure 15. PDE Inhibitors for COPD Report Years Considered
 Figure 16. PDE Inhibitors for COPD Sales Share by Manufacturers in 2024
 Figure 17. Global PDE Inhibitors for COPD Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest PDE Inhibitors for COPD Players: Market Share by Revenue in PDE Inhibitors for COPD in 2024
 Figure 19. PDE Inhibitors for COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global PDE Inhibitors for COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America PDE Inhibitors for COPD Sales Market Share by Country (2020-2031)
 Figure 22. North America PDE Inhibitors for COPD Revenue Market Share by Country (2020-2031)
 Figure 23. United States PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe PDE Inhibitors for COPD Sales Market Share by Country (2020-2031)
 Figure 26. Europe PDE Inhibitors for COPD Revenue Market Share by Country (2020-2031)
 Figure 27. Germany PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific PDE Inhibitors for COPD Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific PDE Inhibitors for COPD Revenue Market Share by Region (2020-2031)
 Figure 34. China PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America PDE Inhibitors for COPD Sales Market Share by Country (2020-2031)
 Figure 42. Latin America PDE Inhibitors for COPD Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Colombia PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa PDE Inhibitors for COPD Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa PDE Inhibitors for COPD Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE PDE Inhibitors for COPD Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of PDE Inhibitors for COPD by Type (2020-2031)
 Figure 53. Global Revenue Market Share of PDE Inhibitors for COPD by Type (2020-2031)
 Figure 54. Global PDE Inhibitors for COPD Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of PDE Inhibitors for COPD by Application (2020-2031)
 Figure 56. Global Revenue Market Share of PDE Inhibitors for COPD by Application (2020-2031)
 Figure 57. Global PDE Inhibitors for COPD Price (US$/Unit) by Application (2020-2031)
 Figure 58. PDE Inhibitors for COPD Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Asthma Monitoring Software Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5Y16546
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Respiratory Disease Test Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2Q16721
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Breath-activated Dry Powder Inhaler Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28Z16251
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Respiratory System Chronic Disease Inhalation Preparation Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24R16205
Thu Sep 25 00:00:00 UTC 2025

Add to Cart